FDA Seeks “Candid” Input from Drug Companies on Rare Disease Treatments

The agency’s new initiative aims to improve regulatory flexibility, incorporate patient perspectives, and explore new approaches to evaluating rare disease data.

By Kerry Dooley Young | October 30, 2026

US regulators are building a framework to better evaluate proposed medical treatments for people with rare diseases, including by considering evidence beyond clinical trial results.

The Food and Drug Administration (FDA) on October 14 called for public feedback on its new Rare Disease Framework. The agency is accepting comments on the initiative through December 11.

Key goals include giving biotech and pharmaceutical companies “greater clarity, consistency, and predictability” to avoid costly mistakes in their research on new drugs and devices. The FDA also said it intends to use “clearly defined milestones” to ensure that patients are consulted early and frequently in the drug development and review process.

The agency is also seeking external expertise to support the customization of regulatory reviews, a necessary step when assessing treatments for rare conditions, which have very small patient populations.

“Patients with rare diseases and their families deserve a regulatory process that addresses the uniqueness of each of their conditions while maintaining the FDA’s rigorous standards,” Amy Comstock Rick, JD, director of the agency’s Rare Disease Innovation Hub, said in a statement.

 “We have to really think about how you do a small study but still have enough information that we can make a reasonable assessment of safety and effectiveness,” Tarver said during the NORD panel.

Rick and three top FDA officials discussed the initiative on October 27 at the National Organization for Rare Disorders (NORD) Breakthrough Summit in Washington, D.C. Joining Rick on a panel were:

  • Michael Davis, MD, PhD, director of the Center for Drug Evaluation and Research (CDER)
  • Karim Mikhail, B. Pharm, MSc, director of the Center for Biologics Evaluation and Research (CBER)
  • Michelle E. Tarver, MD, PhD, director of the Center for Devices and Radiological Health (CDRH)

Major changes are needed to allow the FDA to keep up with the pace of medical discoveries, Mikhail said, adding that new genetic mutations are being discovered each week that may aid in developing treatments for rare diseases. Mikhail, who joined the FDA last year as a senior advisor in the Office of the Commissioner, moved into the top role at CBER this year.

“We need to move from an incremental sort of progress to a true transformational effort,” he told the summit audience. Mikhail noted that there have been many prior FDA initiatives aimed at spurring the development of rare disease treatments, such as the Orphan Drug Act of 1983.

A 2024 report by the Government Accountability Office (GAO) found that the FDA had 18 rare disease-specific programs, most of which had been initiated since 2019.

The 2024 creation of the Rare Disease Innovation Hub at the FDA was intended to streamline and accelerate the various efforts already underway, according to the GAO report.

Initially, the directors of CDER and CBER were to lead the Innovation Hub in close collaboration with CDRH. The FDA now describes the hub as being co-led by all three centers.

At the NORD summit, CDRH director Tarver spoke about the potential for newer approaches to studying rare diseases. She specifically pointed to Bayesian methodology, which combines existing knowledge with new trial data to generate a posterior probability distribution, providing an estimate of treatment effects and the uncertainty around them rather than relying solely on traditional P values.

CDRH’s guidance document describes the method as an “approach for learning from evidence as it accumulates.” Both CBER and CDER issued draft guidance in January 2026 calling for the approach to be used in drug trials.

“We have to really think about how you do a small study but still have enough information that we can make a reasonable assessment of safety and effectiveness,” Tarver said during the NORD panel.

FDA officials also need to consider how researchers may use artificial intelligence (AI) to aid rare disease research, such as by identifying patients who are eligible for trials sooner, she said.

“Can you use it to do digital twins and other simulations? Can you do it to help manage some of the study coordination so that you decrease the burden of a multi-center study? Can you do it to clean the data? All of these are things that we’re looking at that artificial intelligence holds the promise to do, but it is still pretty early in its process,” she explained.

As the FDA considers allowing new approaches to evidence generation, it will need drug developers to be open with the agency about the challenges they face, Tarver said. FDA staff sometimes find that company officials “hide the true question,” forgetting that the agency shares their ultimate goal of getting effective new treatments to market.

“We want to see a product that works get to the patients that need it. We’re all committed to that,” she said. “So, ask us the question that can help you get there faster and more effectively.”

See also, Elizabeth Hart, MD, on the ARC program’s rare disease efforts, and CDER’s Amy Comstock Rick, JD, on the Rare Disease Innovation Hub effort